Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE)
Confident Investing Starts Here:
Sandoz Group Ltd (SDZXF)
In a report issued on June 20, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed last Tuesday at $51.98.
Pauillac has an average return of 32.9% when recommending Sandoz Group Ltd.
According to TipRanks.com, Pauillac is ranked #1277 out of 9634 analysts.
Sandoz Group Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $50.74, a -2.4% downside from current levels. In a report issued on June 9, Barclays also maintained a Buy rating on the stock.
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics today and set a price target of $71.00. The company's shares closed last Friday at $15.01.
According to TipRanks.com, CFA is a 1-star analyst with an average return of -3.4% and a 43.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spyre Therapeutics with a $56.83 average price target, which is a 277.9% upside from current levels. In a report issued on June 17, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Analysts Are Neutral on Top Healthcare Stocks: Bausch Health Companies (BHC), Sanofi (SNYNF)
Analysts fell to the sidelines weighing in on Bausch Health Companies (BHC – Research Report) and Sanofi (SNYNF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bausch Health Companies (BHC) TD Cowen analyst Michael Nedelcovych maintained a Hold rating on Bausch Health Companies yesterday and set a price target of $7.00. The company's shares closed last Friday at $5.71. According to Nedelcovych has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.8% and a 27.9% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Company, Molecular Partners AG, and Coherus Biosciences. Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $8.33, implying a 44.1% upside from current levels. In a report issued on July 25, Truist Financial also maintained a Hold rating on the stock with a $6.78 price target. Sanofi (SNYNF) Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 31 and set a price target of EUR95.00. The company's shares closed last Friday at $92.56, close to its 52-week low of $88.90. According to Pauillac is ranked #974 out of 9914 analysts. Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $127.69, implying a 38.0% upside from current levels. In a report issued on July 17, Deutsche Bank also maintained a Hold rating on the stock with a EUR100.00 price target.
Business Insider
2 hours ago
- Business Insider
Wall Street Analysts Are Bullish on Top Materials Picks
There's a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Titan Cement International N.V. (TTCIF – Research Report) and Wacker Chemie AG (WKCMF – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Titan Cement International N.V. (TTCIF) In a report issued on July 31, Auguste Deryckx Lienart from Kepler Capital maintained a Buy rating on Titan Cement International N.V., with a price target of EUR53.00. The company's shares closed last Friday at $42.50. According to Lienart is ranked #7973 out of 9914 analysts. Titan Cement International N.V. has an analyst consensus of Moderate Buy, with a price target consensus of $61.29. Wacker Chemie AG (WKCMF) In a report issued on July 31, Christian Faitz from Kepler Capital maintained a Buy rating on Wacker Chemie AG, with a price target of EUR104.00. The company's shares closed last Friday at $73.84. According to Faitz is ranked #1048 out of 9914 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Wacker Chemie AG with a $92.17 average price target, which is a 24.8% upside from current levels. In a report issued on July 18, Jefferies also maintained a Buy rating on the stock with a EUR81.00 price target.
Business Insider
2 hours ago
- Business Insider
Analysts Conflicted on These Industrial Goods Names: Elis SA (OtherELSSF) and Rolls-Royce Holdings (OtherRYCEF)
Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Elis SA (ELSSF – Research Report) and Rolls-Royce Holdings (RYCEF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Elis SA (ELSSF) In a report issued on July 31, David Cerdan from Kepler Capital maintained a Buy rating on Elis SA, with a price target of EUR30.00. The company's shares closed last Tuesday at $29.00. Cerdan has an average return of 14.4% when recommending Elis SA. According to Cerdan is ranked #9423 out of 9914 analysts. Currently, the analyst consensus on Elis SA is a Strong Buy with an average price target of $32.84, implying a 13.2% upside from current levels. In a report issued on July 31, UBS also maintained a Buy rating on the stock with a EUR27.00 price target. Rolls-Royce Holdings (RYCEF) Kepler Capital analyst Aymeric Poulain maintained a Hold rating on Rolls-Royce Holdings on July 31 and set a price target of p952.00. The company's shares closed last Friday at $14.19. Poulain has an average return of 43.7% when recommending Rolls-Royce Holdings. According to Poulain is ranked #364 out of 9914 analysts.
